Search Results for Schering-Plough (Corporate Dealmaker)

Advanced Search

Sort ByDate Relevance	Search InCorporate Dealmaker The entire Deal Blogs Network

12 result(s) displayed (1 - 12 of 12):

Merck-Schering Day One (from Corporate Dealmaker)

Merck & Co. (NYSE:MRK) closed its $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP). The deal makes Merck the world's No. 2 drugmaker behind industry juggernaut Pfizer Inc. (NYSE:PFE), which had its own Day One on Oct. 16 after its $68 billion acquisition of Wyeth. Now that Merck and Schering-Plough...

Posted on November 4, 2009 5:04 PM

Merck, Schering integration planning on track (from Corporate Dealmaker)

Teams from Merck & Co. (NYSE:MRK) and Schering-Plough Corp. (NYSE:SGP) are meeting to get a jump on what could be a complex integration. Merck is acquiring Schering for $41.1 billion. The deal is expected to close in the fourth quarter. In its third-quarter earnings announcement on Thursday, Schering noted that "pre-integration...

Posted on October 22, 2009 2:28 PM

What a merged Merck-Schering will look like (from Corporate Dealmaker)

After it closes the $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP), Merck & Co. (NYSE:MRK) will reorganize into five main units, with animal health and consumer healthcare operating as separate business units. The other divisions are global human health, manufacturing and Merck Research Laboratories. The company also will create new...

Posted on August 31, 2009 2:41 PM

Merck exits animal health ... for now (from Corporate Dealmaker)

Merck & Co. (NYSE:MRK) is selling its stake in its animal health joint venture Merial Ltd. to partner French drugmaker Sanofi-Aventis SA (NYSE:SNY) for $4 billion in cash. (The Deal Pipeline subscribers can get the details here.) But the partners might not be separated for long. Here's the story. Merck's exit...

Posted on July 30, 2009 8:45 AM

Medtronic, Abbott settle IP dispute (from Corporate Dealmaker)

Medtronic Inc. (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) have settled a long-running intellectual property dispute. Under terms of the deal, Medtronic will pay Abbott $400 million, and the companies have agreed not to sue one another over coronary stent systems or IP for at least 10 years. Medtronic also agreed to...

Posted on July 27, 2009 2:55 PM

J&J to Schering: We'll arbitrate Remicade (from Corporate Dealmaker)

Come to think of it, why would they not?Quick recap: Merck & Co. (NYSE:MRK) is buying Schering-Plough Corp. (NYSE:SGP) for $41 billion. One of the prime attractions is Schering's rights to co-market -- along with Johnson & Johnson (NYSE:JNJ) -- the $5.9 billion arthritis drug Remicade. The Schering-J&J agreement says...

Posted on May 21, 2009 1:25 PM

A case for pharma, toothpaste and toilet paper (from Corporate Dealmaker)

Does a business model combining pharmaceutical drugs and consumer products make for good corporate strategy? It's a question nearly every pharma giant has considered at one point or another. Well, the findings of a new study from pharmacy benefits management provider Medco Health Solutions adds another data point to the...

Posted on May 13, 2009 1:34 PM

Three more pharma megamergers to go? (from Corporate Dealmaker)

London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...

Posted on April 23, 2009 9:14 AM

As Merck sales drop, pressure builds on Schering deal (from Corporate Dealmaker)

It seems Merck & Co.'s (NYSE:MRK) $41.1 billion acquisition of Schering-Plough Corp. (NYSE:SGP) can't come soon enough -- if, that is, the deal delivers on its promise. Merck saw profit plummet 56% in the first quarter as drug sales dropped, including revenue generated by the cholesterol drugs Zetia and Vytorin....

Posted on April 21, 2009 10:21 AM

Merck, Schering-Plough merge: Where do competitors stand? (from Corporate Dealmaker)

The trend of merging pharmas continued Monday with Merck & Co. (NYSE:MRK) and Schering-Plough Corp. (NYSE:SGP) announcing they would merge in a cash-and-stock deal worth $41.1 billion. The deal makes Merck the No. 2 drugmaker in the U.S. So what does that mean for competitors like Bristol-Myers Squibb Co. and...

Posted on March 9, 2009 9:27 AM

Let there be bio-pharma deals, says trade group chief (from Corporate Dealmaker)

Big Pharmas are cutting costs; Bristol-Myers Squibb Co., Wyeth, Pfizer, Merck & Co., Schering-Plough Corp. and GlaxoSmithKline plc have all announced reductions in their U.S. sales forces. They're also worrying about life under the Democrats.Do they still want to replenish their pipelines with high-priced biotech drugs? James Greenwood, president and...

Posted on November 20, 2008 4:23 PM

Schering-Plough buys out JV partners in China (from Corporate Dealmaker)

To expand its presence in China, Schering-Plough Corp. bought out two local joint venture partners. Schering-Plough started the ventures with Shanghai Pharmaceutical Industry Co. and Shanghai Pharmaceutical Group Co. in 1994. Both companies manufacture allergy and skincare products. Schering will combine the two companies into a subsidiary named Shanghai Schering-Plough...

Posted on August 12, 2008 5:19 PM